Science Current Events | Science News | Brightsurf.com
 

Moffitt Cancer Center Researchers Identify Gene Variations in Lung Cancer Patients That May Help Predict an Individual's Treatment Response

August 09, 2013

TAMPA, Fla. - Researchers at the Moffitt Cancer Center have identified four inherited genetic variants in non-small cell lung cancer patients that can help predict survival and treatment response. Their findings could help lead to more personalized treatment options and improved outcomes for patients.

The researchers analyzed DNA sequence variations in 651 non-small cell lung cancer patients, paying close attention to 53 inflammation-related genes. They found that four of the top 15 variants associated with survival were located on one specific gene (TNFRSF10B). In the study, these variants increased the risk of death as much as 41 percent. The researchers also found that patients with these gene variations had a greater risk of death if their treatment plans included surgery without chemotherapy compared to patients who were treated with chemotherapy following surgery.

"There are few validated biomarkers that can predict survival or treatment response for patients with non-small cell lung cancer," said study lead author Matthew B. Schabath, Ph.D., assistant member of the Cancer Epidemiology Program at Moffitt. "Having a validated genetic biomarker based on inherited differences in our genes may allow physicians to determine the best treatments for an individual patient based on their unique genetics."

Lung cancer is the leading cause of cancer-related deaths in the United States for both men and women. Additionally, non-small cell lung cancer represents more than 80 percent of lung cancer diagnoses.

"Non-small cell lung cancer has an extremely poor five-year survival rate. Only about 16 percent of all patients survive for five years and tragically, only about four percent of patients with late stage disease live longer than five years," explained Schabath. "Part of the difficulty in treating lung cancer is the genetic diversity of patients and their tumors. Using a personalized medicine approach to match the best treatment option to a patient based on his or her genetics will lead to better outcomes."

The researchers noted that there has been no published data examining the association of these four specific variants on cancer risk or outcome, although studies have reported associations with other gene variants in the same gene family as TNFRSF10B.

The study can be found in the July issue of Carcinogenesis.

The work was supported by funding from the State of Florida through the James & Esther King Biomedical Research Program (09KN-15), a National Institutes of Health SPORE grant (P50 CA119997), an American Cancer Society grant (93-032-13), and a grant from the National Cancer Institute (5 UC2 CA 148322-02).

Moffitt Cancer Center


Related Lung Cancer Current Events and Lung Cancer News Articles


Palliative, hospice care lacking among dying cancer patients, Stanford researcher finds
Medical societies, including the American Society of Clinical Oncology, recommend that patients with advanced cancer receive palliative care soon after diagnosis and receive hospice care for at least the last three days of their life.

Study reveals protein that dials immune responses up and down
Research led by scientists at the Sanford Burnham Prebys Medical Discovery Institute (SBP) has identified a new regulator of immune responses.

Living near a landfill could damage your health
According to research published today in the International Journal of Epidemiology, health is at risk for those who live within five kilometres of a landfill site.

Lung cancer survival rate increases by 73 percent if caught early
The UK Lung cancer screening trial (UKLS) has been successfully completed and demonstrated that patients with a high risk of developing lung cancer can be identified with early stage disease and have up to a 73% chance of surviving for five years or more.

Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types
The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.

Evidence of link between cancer & light therapy inconclusive but warrants consideration
Two new studies raise enough questions about a possible link between childhood cancer and light therapy for newborn jaundice that clinicians should exercise caution in prescribing the treatment for infants whose jaundice is likely to resolve on its own, a pediatric oncologist from Dana-Farber/Boston Children's Cancer and Blood Disorders Center argues in an editorial published today by the journal Pediatrics.

Researchers find blood marker that determines who will respond to colorectal cancer drug
Cancer researchers have identified a marker that shows up in a blood test that determines which patients with colorectal cancer that has spread would benefit from receiving the drug cetuximab.

Preliminary results comparing PD-L1 IHC diagnostic assays in lung cancer released
A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the "BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT" at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19.

Protein may predict response to immunotherapy in patients with metastatic melanoma
A protein called Bim may hold the clue to which patients may be successful on immunotherapy for metastatic melanoma, according to the results of a study by Mayo Clinic researchers led by senior author Haidong Dong, M.D., Ph.D., and published online in the May 5 edition of JCI Insight.

Cancer may drive health problems as people age
A new study indicates that cancer may have negative impacts on both the physical and mental health of individuals as they age.
More Lung Cancer Current Events and Lung Cancer News Articles

How to Survive Lung Cancer - A Practical 12-Step Plan

How to Survive Lung Cancer - A Practical 12-Step Plan
by Michael Lloyd (Author)


Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer Specialist and Associate Professor at Harvard Medical School, this book combines what the doctors tell you with critical information they don't tell you. Visit www.SurviveLungCancer.com for chapter summaries.

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC


This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

Living With A Diagnosis Of Lung Cancer

Living With A Diagnosis Of Lung Cancer
by Joan Schiller MD (Author)


"Living With a Diagnosis of Lung Cancer” is an easy-to-understand booklet written to help lung cancer patients understand their diagnosis and their options as they face the disease. Lung cancer claims more lives than breast, prostate, and colon cancers combined. In fact, over 288,000 people are diagnosed each year in the U.S. People with lung cancer often are told, "Get your affairs in order." But, there is hope for those diagnosed with lung cancer. Thanks to research advances, there are options available to patients diagnosed regardless of the stage of the disease. Much progress is being made with new treatments being developed and tested each day. This valued resource will help you know what questions to ask of your medical team and can help you understand your treatments...

Living with Lung Cancer--My Journey

Living with Lung Cancer--My Journey
by Thomas E. Cappiello (Author)


On October 5 2007, Thomas Cappiello was diagnosed with inoperable Stage IIIA locally-advanced adenocarcinoma (Non-Small Cell Lung Cancer), an incurable disease. This book is the inspirational story of how he beat the odds and survived and thrived in the face of this devastating illness. This book is for patients and caregivers who want to know what life is like after getting a cancer diagnosis. The story is about overcoming the emotional turmoil and devastation of a cancer diagnosis, dealing with the disease, and making choices. Most of all, it's about living a full life each day. Cancer patients suddenly realize that time is a precious gift from God and there is no time to waste. By telling his story Cappiello seeks to inspire cancer patients to fight hard and live, with whatever time...

100 Questions  &  Answers About Lung Cancer (100 Questions and Answers)

100 Questions & Answers About Lung Cancer (100 Questions and Answers)
by Joan H. Schiller (Author), Amy Cipau (Author)


EMPOWER YOURSELF! No one with lung cancer needs to be alone in their fight against this disease. 100 Questions & Answers About Lung Cancer, Third Edition, guides patients and their families through diagnosis, treatment and survivorship. Providing both the doctor’s and patient’s point of view, this book is a complete guide to understanding treatment options, post-treatment quality of life, sources of support, and much more. Through 100 Questions & Answers About Lung Cancer, Third Edition, expert authors use their experiences with patients to provide support and hope to the tens of thousands of people coping with lung cancer.

You Can Beat Lung Cancer: Using Alternative/Integrative Interventions

You Can Beat Lung Cancer: Using Alternative/Integrative Interventions
by Carl O. Helvie (Author)


Can you overcome lung cancer without harsh chemicals, surgery and debilitation? Are alternative interventions effective? Why do conventional physicians not use them? Can you prevent cancer recurrences and live into old age without chronic diseases and prescribed medications? This book answers these and other questions.

This is one of the most comprehensive books available on alternative treatments for lung cancer. It explains the treatments used successfully by a health professional/cancer survivor of 36 years and by some of the leading medical and health practitioners currently in the field. G. Edward Griffin, Author of World Without Cancer, The Politics of Cancer Therapy, and other books and films. Recipient of the Telly Award for Excellence in Television Production. President of...

Johns Hopkins Patients' Guide To Lung Cancer

Johns Hopkins Patients' Guide To Lung Cancer
by Justin F. Klamerus (Author), Julie R. Brahmer (Author), David S Ettinger (Author)


Johns Hopkins Patients' Guide to Lung Cancer is a concise, easy-to-follow “how to” guide that puts you on the path to wellness by explaining lung cancer treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman's terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment.

Lung Cancer: A Guide to Diagnosis and Treatment

Lung Cancer: A Guide to Diagnosis and Treatment
by Walter J. Scott MD (Author)


What is my prognosis? What are my treatment options? Which therapies would be the most effective for my stage of lung cancer? These and other frequently asked questions are addressed in this crucial reference designed to help patients educate themselves and obtain the best possible treatments. The completely revised second edition has been updated to include a discussion of the movement towards customized chemotherapy; treatment options for early-stage lung cancer including minimally invasive surgery; and the most promising treatments, among them multimodality therapy—a combination of surgery, chemotherapy, and radiation. Dr. Scott also surveys tests for early detection of lung cancer, talks about the importance of cancer staging, examines alternative treatments, and offers advice on...

WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (IARC WHO Classification of Tumours)

WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (IARC WHO Classification of Tumours)
by International Agency for Research on Cancer (Author)


WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart is the seventh volume in the Fourth Edition of the WHO series on histological and genetic typing of human tumors.

This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome.

This book is in the series commonly referred to as the "Blue Book" series.

Lung Cancer: Treatment and Research

Lung Cancer: Treatment and Research
by Karen L. Reckamp (Editor)


This book describes the molecular mechanisms of lung cancer development and progression that determine therapeutic interventions in the era of genomics, when the rapid evolution in lung cancer diagnosis and treatment necessitates critical review of new results to integrate advances into practice.  The text opens with background and emerging information regarding the molecular biology of lung cancer pathogenesis.  Updated results regarding lung cancer prevention and screening are discussed, followed by chapters on diagnostic techniques and pathological evaluation.  This leads on to a detailed presentation of treatment modalities, from surgery and radiation therapy to standard chemotherapy and targeted agents. The coverage includes resistance to therapy and the emergence of immunotherapy...

© 2017 BrightSurf.com